New Real-World Evidence Systematic Review Finds Efficacy of Biosimilars on Psoriasis Comparable to Biologic

A systematic review recently published in the Journal of Dermatological Treatment found that several biosimilars were as effective as their biosimilar equivalents in the treatment of psoriasis. The review used real-world evidence (RWE) from several observational studies. Several drugs were included in the analysis, including adalimumab, etanercept, and infliximab.

According to Laura Joszt, the studies that examined Adalimumab found that, “The studies found similar efficacy following the switch to the biosimilar in patients with psoriasis. Three studies evaluated articular disease: One found a possible loss of response in patients with axial disease, while the other 2 found no loss of disease control after the switch. The sample size in the study showing a possible loss of response was small. There was an increase in the rate of mild adverse events (AEs) following the switch to the biosimilar in 2 of the 5 studies.”

To read more, click here.

(Source: AJMC, November 16^th, 2022)